Fig. 5
Effects of RC48 and dabrafenib combination treatment on global gene expression profile. Gene expression studies were conducted using RNA-seq in A2058 cells treated with vehicle control, 2 μg/mL RC48, 1 μM DAB, or their combination for 24 h. Each group represents triplicate samples. A, B The expression of DEGs in A2058 cells between the vehicle and RC48 plus DAB combination treatment. Upregulated and downregulated genes are shown in red and green, respectively. Values are presented as the log10 of tag counts. C Number of overlapping DEGs in cells treated with the combination compared to the VEH-treated cells. D–F Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of DEGs in the RC48 (D), DAB (E), and RC48 + DAB (F) treated samples compared with the VEH-treated samples in A2058 cells. G Analysis of the PI3K/AKT pathway, MAPK pathway, AMPK pathway, and FOXO pathway. GAPDH was used as the loading control. Statistical significance was assessed using an unpaired t-test; *p < 0.05, **p < 0.01, ***p < 0.001 compared with VEH groups